sglt2 vs glp 1 vs dpp4 Comparison of GLP-1 receptor agonists and DPP-4 inhibitors sitagliptin [TUSOM | Pharmwiki]

A lot of clinicians think they do, but he is not persuaded

GLP-1 medications carry serious risks, including the risk of thyroid C-cell tumors and medullary thyroid carcinoma (MTC)

The serious side effects such as pancreatitis and kidney issues are rare across all options

However, particular caution may be needed regarding ophthalmic complications

In their new guidelines, the ACC noted that modern obesity medications, including semaglutide and tirzepatide, have been proven more effective than lifestyle interventions at not only weight loss, but at reducing overall cardiovascular disease (CVD) risk, with fewer risks than procedure-based interventions

Poczenie obu sygnaw daje efekt metaboliczny silniejszy ni agonizm pojedynczego receptora